# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2025 Earnings Results

**Report date:** 2025-04-29 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2025

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.87%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $8.22 | N/A | +24.32% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline. However, they noted external factors that could impact future performance.

**Key quotes:**

> Management highlighted strong performance in key product lines.

> They acknowledged ongoing challenges in the market but remain focused on innovation.

### Guidance Changes

No guidance updates were provided in this earnings report.

### What It Means

Regeneron Pharmaceuticals reported a strong earnings per share, beating expectations significantly. However, the stock fell by nearly 7% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance amidst market challenges.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2025_